Prurigo Nodularis NEMLUVIO is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.
Atopic Dermatitis NEMLUVIO is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy.
Please verify that you are a U.S. Healthcare Professional
This information is intended for U.S. Healthcare Professionals.
You are about to leave this website for another website maintained by a third party over whom Galderma has no control. Galderma is not responsible for the content of non-Galderma websites and shall have no liability for any damages or injuries of any kind arising from such content or information.
Links to other websites are provided as a convenient resource to the users of this website only.
